Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study

J. Špaček, J. Kestřánek, P. Jílek, D. Leško, S. Plucnarová, V. Buchta,

. 2017 ; 60 (4) : 260-265. [pub] 20170109

Language English Country Germany

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc17013309

Grant support
NV15-29225A MZ0 CEP Register

Vulvovaginal candidiasis (VVC) is a hormonal-dependent infection but in contrast to sporadic VVC, therapy of recurrent vulvovaginal candidiasis (RVVC) is still unsolved. Long-term administration of medroxyprogesterone acetate was evaluated for the management of RVVC. Overall, 20 patients were treated with Depo-Provera; 14 patients were treated with Provera. Gestagen therapy was evaluated based on visual analogue scale (VAS), the frequency of attacks, the side effects of gestagens and the consumption of antifungals. There was a reduced symptomatology in both of the groups and substantial reduction in antifungal drug consumption during the second year of gestagen use. Twenty-four patients (70.6%) evaluated their condition regarding the vulvovaginal area as improvement (VAS decrease of 3-5 points). Five patients (14.7%) mentioned minimal or no improvement. Further, a number of antifungal drug-treated episodes dropped dramatically during the study period. Both regimes provided similar results, but five patients from the Depo-Provera group had to withdraw from gestagen therapy. Gestagen supplementation ameliorated the quality of life for the majority of patients with RVVC and suggested a potential role in the management of this syndrome, even if beneficial effect was evident after longer application, and some patients met with side effects that led to an interruption of therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013309
003      
CZ-PrNML
005      
20201031111241.0
007      
ta
008      
170413s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1111/myc.12593 $2 doi
035    __
$a (PubMed)28066940
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Špaček, Jiří $u Department of Obstetrics and Gynaecology, University Hospital, Charles University, Hradec Kralove, Czech Republic.
245    10
$a Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study / $c J. Špaček, J. Kestřánek, P. Jílek, D. Leško, S. Plucnarová, V. Buchta,
520    9_
$a Vulvovaginal candidiasis (VVC) is a hormonal-dependent infection but in contrast to sporadic VVC, therapy of recurrent vulvovaginal candidiasis (RVVC) is still unsolved. Long-term administration of medroxyprogesterone acetate was evaluated for the management of RVVC. Overall, 20 patients were treated with Depo-Provera; 14 patients were treated with Provera. Gestagen therapy was evaluated based on visual analogue scale (VAS), the frequency of attacks, the side effects of gestagens and the consumption of antifungals. There was a reduced symptomatology in both of the groups and substantial reduction in antifungal drug consumption during the second year of gestagen use. Twenty-four patients (70.6%) evaluated their condition regarding the vulvovaginal area as improvement (VAS decrease of 3-5 points). Five patients (14.7%) mentioned minimal or no improvement. Further, a number of antifungal drug-treated episodes dropped dramatically during the study period. Both regimes provided similar results, but five patients from the Depo-Provera group had to withdraw from gestagen therapy. Gestagen supplementation ameliorated the quality of life for the majority of patients with RVVC and suggested a potential role in the management of this syndrome, even if beneficial effect was evident after longer application, and some patients met with side effects that led to an interruption of therapy.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a antifungální látky $x terapeutické užití $7 D000935
650    _2
$a Candida $x izolace a purifikace $x ultrastruktura $7 D002175
650    _2
$a kandidóza vulvovaginální $x farmakoterapie $x mikrobiologie $7 D002181
650    _2
$a management nemoci $7 D019468
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a medroxyprogesteronacetát $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D017258
650    _2
$a pilotní projekty $7 D010865
650    _2
$a progestiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011372
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $7 D011788
650    _2
$a recidiva $7 D012008
650    _2
$a čas $7 D013995
650    _2
$a vizuální analogová stupnice $7 D064232
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kestřánek, Jan $u Department of Obstetrics and Gynaecology, University Hospital, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Jílek, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Leško, Daniel $u Department of Obstetrics and Gynaecology, University Hospital, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Plucnarová, Silvie $u Department of Clinical Microbiology, University Hospital, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Buchta, Vladimír $u Department of Biological and Medical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic. Department of Clinical Microbiology, University Hospital, Charles University, Hradec Kralove, Czech Republic.
773    0_
$w MED00010272 $t Mycoses $x 1439-0507 $g Roč. 60, č. 4 (2017), s. 260-265
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28066940 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20201031111240 $b ABA008
999    __
$a ok $b bmc $g 1199774 $s 974087
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 60 $c 4 $d 260-265 $e 20170109 $i 1439-0507 $m Mycoses $n Mycoses $x MED00010272
GRA    __
$a NV15-29225A $p MZ0
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Archiving options